First patient enrolled in phase 3 MicroStat program

Eyenovia has enrolled the first patient in its phase 3 MicroStat program for pharmacologic mydriasis, according to a press release.
A fixed combination of phenylephrine 2.5% and tropicamide 1% ophthalmic solution will be administered as a micro-dose using the Optejet dispenser, the release said.
The randomized, double-masked, multicenter superiority MIST-1 and MIST-2 studies, each including approximately 65 participants, will investigate the safety and efficacy of the ophthalmic solution. In both studies, the primary endpoint is mean change in baseline pupil diameter 35 minutes after

Full Story →